The FDA's decision stems from the review of a 5-year trial designed to evaluate cardiac risk with the weight-loss drug. "We believe that the risks of lorcaserin outweigh its benefits," the FDA said.
News Alerts
Original Article: Lorcaserin (Belviq) Withdrawn From US Market Due to Cancer Risk